*In a randomized, double-blind, placebo-controlled clinical trial, onset of relief was experienced within 4 hours by 69.8% of BERINERT treatment group and 42.9% of placebo group. For subjects who did not respond within that time frame, study design allowed use of rescue medications as follows: placebo for 20 IU/kg body weight BERINERT treatment group and 20 IU/kg body weight BERINERT for placebo group. Median time to complete resolution of HAE symptoms was 4.9 hours in a phase 3 clinical trial and 8.4 hours in an open-label extension.
BERINERT is the only C1 esterase inhibitor (C1-INH) approved for on-demand treatment of acute abdominal, facial, or laryngeal attacks of HAE in adults and children.
BERINERT is an intravenous (IV) infusion that you can learn to self-administer at home or anywhere that’s convenient. In fact, a study showed that 95% of BERINERT infusions were given outside of healthcare settings.1
No matter where you are on your journey with HAE, you’re never more than a phone call away from the helpful services of BERINERT Connect, formerly known as B.E.N. Once your doctor prescribes BERINERT, you’ll have access to help getting started, co-pay support, connections with others living with HAE, and so much more.
Taking a few moments to prepare for your visits to the doctor can help make them more productive.
Use this discussion guide to help remember and communicate important details that can help you and your doctor have a more thorough conversation.
Reference: 1. Riedl MA, Bygum A, Lumry W, et al. Safety and usage of C1-inhibitor in hereditary angioedema: BERINERT registry data. J Allergy Clin Immunol Pract. 2016;4(5):963-971.